Global Artificial Pancreas Device System Market Research Report 2019 (Includes Business Impact of COVID-19)

                                          
"The ongoing Coronavirus (COVID-19) pandemic is re-shaping everything from global economies to product categories, pricing, and stock availability to the consumer behavior. The final report is updated to address the impact of COVID-19 on the Artificial Pancreas Device System market.

Trusted Business Insights is tracking mining/oil and gas, transportation, employment services, travel arrangements, and the leisure and hospitality sector closely as they are likely to be the hardest-hit sectors. Utilities, local pharma, diagnostics, consumer goods and durables, agro chem and fertilizers, and telecommunications are the sectors that will be weathering the COVID-19 storm and most likely come out relatively unscathed. Interdependencies of sectors are factored in our research report on the Artificial Pancreas Device System market."
Sometimes an artificial pancreas device system is referred to as a closed-loop system, an automated insulin delivery system, or an autonomous system for glycemic control.
Based on device type the market is segmented into control - to - range (CTR) system, threshold suspended device system and control - to - target (CTT) system.

The global Artificial Pancreas Device System market is valued at 110 million US$ in 2018 is expected to reach 420 million US$ by the end of 2025, growing at a CAGR of 18.6% during 2019-2025.
This report focuses on Artificial Pancreas Device System volume and value at global level, regional level and company level. From a global perspective, this report represents overall Artificial Pancreas Device System market size by analyzing historical data and future prospect. Regionally, this report focuses on several key regions: North America, Europe, China and Japan.
At company level, this report focuses on the production capacity, ex-factory price, revenue and market share for each manufacturer covered in this report.

The following manufacturers are covered:
    Medtronic
    Johnson & Johnson
    TypeZero Technologies
    Tandem Diabetes
    Pancreum
    Insulet
    Beta Bionics
    Animas Corporation
    LLC
    Bigfoot Biomedical

Segment by Regions
    North America
    Europe
    China
    Japan

Segment by Type
    Control-to-Range (CTR) System
    Threshold Suspended Device System
    Control - to - Target (CTT) System

Segment by Application
    Hospital
    Clinic
    Others